Header Logo

Connection

HANA EL SAHLY to Antibodies, Viral

Back to Details
This is a "connection" page, showing publications HANA EL SAHLY has written about Antibodies, Viral.
HANA EL SAHLY
Connection Strength
2.707
Antibodies, Viral
  1. A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure-Proximal Design but Requires Far Fewer Blood Samples. J Infect Dis. 2026 Mar 17; 233(3):e646-e650.
    View in: PubMed
    Score: 0.633
  2. Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trials. Vaccine. 2026 Apr 02; 77:128380.
    View in: PubMed
    Score: 0.157
  3. Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine. J Infect Dis. 2025 Oct 15; 232(4):971-981.
    View in: PubMed
    Score: 0.154
  4. Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial. Nat Commun. 2024 09 11; 15(1):7954.
    View in: PubMed
    Score: 0.142
  5. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clin Infect Dis. 2024 06 14; 78(6):1757-1768.
    View in: PubMed
    Score: 0.140
  6. Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial. J Infect Dis. 2022 11 11; 226(10):1731-1742.
    View in: PubMed
    Score: 0.125
  7. Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl J Med. 2022 03 17; 386(11):1046-1057.
    View in: PubMed
    Score: 0.119
  8. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022 Jan 07; 375(6576):43-50.
    View in: PubMed
    Score: 0.117
  9. Topical Imiquimod Does Not Provide an Adjuvant Effect When Administered With Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults. J Infect Dis. 2021 11 22; 224(10):1712-1719.
    View in: PubMed
    Score: 0.117
  10. An evaluation of cytokine and cellular immune responses to heterologous prime-boost vaccination with influenza A/H7N7-A/H7N9 inactivated vaccine. Hum Vaccin Immunother. 2020 12 01; 16(12):3138-3145.
    View in: PubMed
    Score: 0.105
  11. Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination. Vaccine. 2019 05 01; 37(19):2561-2568.
    View in: PubMed
    Score: 0.098
  12. Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial. Vaccine. 2017 02 07; 35(6):923-928.
    View in: PubMed
    Score: 0.084
  13. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-na?ve subjects. Vaccine. 2015 Sep 22; 33(39):5225-34.
    View in: PubMed
    Score: 0.075
  14. MF59™ as a vaccine adjuvant: a review of safety and immunogenicity. Expert Rev Vaccines. 2010 Oct; 9(10):1135-41.
    View in: PubMed
    Score: 0.054
  15. A Phase 1 Double-Blinded Trial to Evaluate Safety, Immunogenicity, and Dosing of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults. J Infect Dis. 2026 Mar 17; 233(3):e641-e645.
    View in: PubMed
    Score: 0.040
  16. Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccination. Vaccine. 2026 Jan 01; 69:127959.
    View in: PubMed
    Score: 0.039
  17. Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59?. Vaccine. 2025 02 15; 47:126702.
    View in: PubMed
    Score: 0.036
  18. Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases. Nat Commun. 2024 Aug 29; 15(1):7469.
    View in: PubMed
    Score: 0.036
  19. Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial. J Infect Dis. 2024 02 14; 229(2):327-340.
    View in: PubMed
    Score: 0.034
  20. Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial. Int J Infect Dis. 2023 Dec; 137:28-39.
    View in: PubMed
    Score: 0.033
  21. Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial. Viruses. 2023 09 29; 15(10).
    View in: PubMed
    Score: 0.033
  22. Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration. Nat Commun. 2023 06 17; 14(1):3605.
    View in: PubMed
    Score: 0.033
  23. Persistence of Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in Healthy Adults: 2 Years of Follow-up Compared With Natural Infection. J Infect Dis. 2023 05 29; 227(11):1303-1312.
    View in: PubMed
    Score: 0.033
  24. Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial. Sci Transl Med. 2023 04 19; 15(692):eade9078.
    View in: PubMed
    Score: 0.032
  25. Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal quadrivalent inactivated influenza vaccine in young adults - A randomized clinical trial. Vaccine. 2023 04 17; 41(16):2716-2722.
    View in: PubMed
    Score: 0.032
  26. Associations of Immunogenicity and Reactogenicity After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine in the COVE and TeenCOVE Trials. Clin Infect Dis. 2023 01 13; 76(2):271-280.
    View in: PubMed
    Score: 0.032
  27. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Rep Med. 2022 07 19; 3(7):100679.
    View in: PubMed
    Score: 0.031
  28. Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65?years and older. Vaccine. 2021 02 22; 39(8):1339-1348.
    View in: PubMed
    Score: 0.028
  29. Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. Vaccine. 2017 03 23; 35(13):1675-1682.
    View in: PubMed
    Score: 0.021
  30. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA. 2015 Jul 21; 314(3):237-46.
    View in: PubMed
    Score: 0.019
  31. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Vaccine. 2015 Jan 01; 33(1):163-73.
    View in: PubMed
    Score: 0.018
  32. Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. J Infect Dis. 2012 Oct 01; 206(7):1069-77.
    View in: PubMed
    Score: 0.015
  33. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok?) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine. 2011 Oct 13; 29(44):7733-9.
    View in: PubMed
    Score: 0.014
  34. Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine. 2011 Oct 06; 29(43):7357-63.
    View in: PubMed
    Score: 0.014
  35. A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine. 2010 Apr 09; 28(17):3025-9.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.